Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2021-11-15 Director's Dealing
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
Director's Dealing 2021
Director's Dealing
2021-11-15 English
Director's Dealing 2021
Director's Dealing
2021-11-05 English
Director's Dealing 2021
Director's Dealing
2021-11-05 English
Director's Dealing 2021
Director's Dealing
2021-11-05 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The provided document text appears to be heavily encoded or corrupted, containing mostly non-readable characters and no discernible financial, regulatory, or corporate filing content. There are no clear indications of report titles, fiscal periods, regulatory bodies, or keywords that would allow classification into any specific filing category. The document length is 15,000 characters, which is substantial, but the content does not contain meaningful text to identify it as a financial report, announcement, or any other specific filing type. Given the lack of identifiable content and the fallback rule, the document should be classified as a Regulatory Filing (RNS), which serves as a catch-all category for miscellaneous or unclear filings.
2021-11-04 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by ABVC BioPharma, Inc. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities for sale to the public. The document includes details about the types of securities to be registered, the maximum aggregate offering price, and the terms of the offering. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not merely an announcement of a report, so it is not RPA or RNS. Confidence is high given the clear identification of the form and its purpose.
2021-10-29 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.